Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669157 | 0.91 | RAF1 (0.37) | RAF1MAPK14KDM4EALOX15APOBEC3A | |
| SCHEMBL669934 | 0.80 | RAF1 (0.34) | RAF1MAPK14 | |
| SCHEMBL669158 | 0.76 | CYP2E1 (0.33) | RAF1KDM4EALOX15APOBEC3AHSD17B10 | |
| SCHEMBL669139 | 0.76 | CYP2E1 (0.32) | RAF1 | |
| SCHEMBL1441015 | 0.75 | RAF1 (0.33) | RAF1MAPK14 | |
| SCHEMBL15512298 | 0.73 | CYP2E1 (0.51) | — | |
| SCHEMBL15511306 | 0.73 | CYP2E1 (0.51) | — | |
| SCHEMBL1441006 | 0.72 | MAPK14 (0.32) | RAF1MAPK14 | |
| SCHEMBL669791 | 0.71 | KDM4E (0.40) | KDM4EALOX15HSD17B10L3MBTL1 | |
| SCHEMBL670080 | 0.70 | IDH1 (0.33) | RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |